IgG1 allotypes influence the pharmacokinetics of therapeutic monoclonal antibodies through FcRn binding

Journal of Immunology

Volumn 196, Issue 2, 2016, Pages 607-613

  Ternant, David ^a,b   Arnoult, Christophe ^a   Pugniere, Martine ^c   Dhomme Le, Christine ^a   Drocourt, Daniel ^d   Perouzel, Eric ^d   Passot, Christophe ^a,b   Baroukh, Nadine ^a   Mulleman, Denis ^a   LrardTiraby, Ge ^d   LWatier, Herve ^a,b   Paintaud, Gilles ^a,b   Gouilleux Gruart, Valerie ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c UNIV MONTPELLIER   (France)

^d Zone industrielle de Montaudran   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CETUXIMAB; FC RECEPTOR; IMMUNOGLOBULIN ALLOTYPE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; PANITUMUMAB; RITUXIMAB; TRASTUZUMAB; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN G;

ADULT; AGED; ARTICLE; CELL ASSAY; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SPONDYLARTHRITIS; SURFACE PLASMON RESONANCE; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; METABOLISM; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIBODIES, MONOCLONAL; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN ALLOTYPES; IMMUNOGLOBULIN G; INFLIXIMAB; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, FC; SPONDYLARTHRITIS; SURFACE PLASMON RESONANCE;

EID: 84954165258     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501780     Document Type: Article

References (49)

1. Brambell, F. W., W. A. Hemmings, and I. G. Morris. 1964. A theoretical model of gamma-globulin catabolism. Nature 203: 1352-1354.
2. Simister, N. E., and K. E. Mostov. 1989. An Fc receptor structurally related to MHC class I antigens. Nature 337: 184-187.
3. Raghavan, M., V. R. Bonagura, S. L. Morrison, and P. J. Bjorkman. 1995. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 34: 14649-14657.
4. Chaudhury, C., S. Mehnaz, J. M. Robinson, W. L. Hayton, D. K. Pearl, D. C. Roopenian, and C. L. Anderson. 2003. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J. Exp. Med. 197: 315-322.
5. Andersen, J. T., B. Dalhus, J. Cameron, M. B. Daba, A. Plumridge, L. Evans, S. O. Brennan, K. S. Gunnarsen, M. Bjøra°s, D. Sleep, and I. Sandlie. 2012. Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat. Commun. 3: 610 doi:10.1038/ncomms1607.
6. Story, C. M., J. E. Mikulska, and N. E. Simister. 1994. A major histocompati-bility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. J. Exp. Med. 180: 2377-2381.
7. Junghans, R. P., and C. L. Anderson. 1996. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl. Acad. Sci. USA 93: 5512-5516.
8. Roopenian, D. C., and S. Akilesh. 2007. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7: 715-725.
9. Oganesyan, V., M. M. Damschroder, K. E. Cook, Q. Li, C. Gao, H. Wu, and W. F. Dall'Acqua. 2014. Structural insights into neonatal Fc receptor-based recycling mechanisms. J. Biol. Chem. 289: 7812-7824.
10. Ward, E. S., and R. J. Ober. 2009. Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv. Immunol. 103: 77-115.
11. Vidarsson, G., A. M. Stemerding, N. M. Stapleton, S. E. Spliethoff, H. Janssen, F. E. Rebers, M. de Haas, and J. G. van de Winkel. 2006. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood 108: 3573-3579.
12. Baker, K., T. Rath, M. Pyzik, and R. S. Blumberg. 2014. The Role of FcRn in Antigen Presentation. Front. Immunol. 5: 408 doi:10.3389/fimmu.2014.00408.
13. Cervenak, J., B. Bender, Z. Schneider, M. Magna, B. V. Carstea, K. Liliom, A. Erdei, Z. Bosze, and I. Kacskovics. 2011. Neonatal FcR overexpression boosts humoral immune response in transgenic mice. J. Immunol. 186: 959-968.
14. Baker, K., T. Rath, M. B. Flak, J. C. Arthur, Z. Chen, J. N. Glickman, I. Zlobec, E. Karamitopoulou, M. D. Stachler, R. D. Odze, et al. 2013a. Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colo-rectal cancer. Immunity 39: 1095-1107.
15. Pyzik, M., T. Rath, W. I. Lencer, K. Baker, and R. S. Blumberg. 2015. FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin. J. Immunol. 194: 4595-4603.
16. Shields, R. L., A. K. Namenuk, K. Hong, Y. G. Meng, J. Rae, J. Briggs, D. Xie, J. Lai, A. Stadlen, B. Li, et al. 2001. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276: 6591-6604.
17. Schmidt, M. M., S. A. Townson, A. J. Andreucci, B. M. King, E. B. Schirmer, A. J. Murillo, C. Dombrowski, A. W. Tisdale, P. A. Lowden, A. L. Masci, et al. 2013. Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface. Structure 21: 1966-1978.
18. Kuo, T. T., and V. G. Aveson. 2011. Neonatal Fc receptor and IgG-based therapeutics. MAbs 3: 422-430.
19. Santagostino, E., C. Negrier, R. Klamroth, A. Tiede, I. Pabinger-Fasching, C. Voigt, I. Jacobs, and M. Morfini. 2012. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 120: 2405-2411.
20. Zalevsky, J., A. K. Chamberlain, H. M. Horton, S. Karki, I. W. L. Leung, T. J. Sproule, G. A. Lazar, D. C. Roopenian, and J. R. Desjarlais. 2010. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28: 157-159.
21. Ko, S.-Y., A. Pegu, R. S. Rudicell, Z. Y. Yang, M. G. Joyce, X. Chen, K. Wang, S. Bao, T. D. Kraemer, T. Rath, et al. 2014. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514: 642-645.
22. Ward, E. S., S. C. Devanaboyina, and R. J. Ober. 2015. Targeting FcRn for the modulation of antibody dynamics. Mol. Immunol. 67(2 Pt. A): 131-141.
23. Lefranc, G., and M.-P. Lefranc. Gm allotypes and Gm haplotypes. Allotypes. In IMGT Repertoire (IG and TR). IMGT, the international ImMunoGeneTics information system. Available at: http://www.imgt.org/IMGTrepertoire/Proteins/allotypes/human/IGH/IGHC/Hu-IGHCallotypes1.html Accessed: December 8, 2015.
24. Dugoujon, J.-M., S. Hazout, F. Loirat, B. Mourrieras, B. Crouau-Roy, and A. Sanchez-Mazas. 2004. GM haplotype diversity of 82 populations over the world suggests a centrifugal model of human migrations. Am. J. Phys. Anthropol. 125: 175-192.
25. Clark, M. R. 1997. IgG effector mechanisms. Chem. Immunol. 65: 88-110.
26. Jefferis, R., and M.-P. Lefranc. 2009. Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs 1: 332-338.
27. Stapleton, N. M., J. T. Andersen, A. M. Stemerding, S. P. Bjarnarson, R. C. Verheul, J. Gerritsen, Y. Zhao, M. Kleijer, I. Sandlie, M. de Haas, et al. 2011. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat. Commun. 2: 599 doi:10.1038/ncomms1608.
28. Oxelius, V. A., and M. M. Eibl. 1996. Different Gm allotype amounts in human intravenous immunoglobulin (IVIG) preparations; survival of foreign Gm allo-types in immunodeficient patients. Clin. Exp. Immunol. 106: 203-207.
29. Pham, T., B. Fautrel, E. Dernis, P. Goupille, F. Guillemin, X. Le Loët, P. Ravaud, P. Claudepierre, C. Miceli-Richard, M. de Bandt, et al; Club Rhumatismes et Inflammation (CRI/SFR). 2007. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine 74: 638-646.
30. Ternant, D., D. Mulleman, D. Degenne, S. Willot, J.-M. Guillaumin, H. Watier, P. Goupille, and G. Paintaud. 2006. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther. Drug Monit. 28: 169-174.
31. Magdelaine-Beuzelin, C., S. Vermeire, M. Goodall, F. Baert, M. Noman, G. V. Assche, M. Ohresser, D. Degenne, J.-M. Dugoujon, R. Jefferis, et al. 2009. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet. Genomics 19: 383-387.
32. Dirks, N. L., and B. Meibohm. 2010. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet. 49: 633-659.
33. Lefranc, M.-P., and G. Lefranc. 2012. Human Gm, Km, and Am allotypes and their molecular characterization: a remarkable demonstration of polymorphism. Methods Mol. Biol. 882: 635-680.
34. Passot, C., N. Azzopardi, S. Renault, N. Baroukh, C. Arnoult, M. Ohresser, M. Boisdron-Celle, E. Gamelin, H. Watier, G. Paintaud, and V. Gouilleux-Gruart. 2013. Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies. MAbs 5: 614-619.
35. Morton, T. A., and D. G. Myszka. 1998. Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors. Methods Enzymol. 295: 268-294.
36. Vaughn, D. E., and P. J. Bjorkman. 1997. High-affinity binding of the neonatal Fc receptor to its IgG ligand requires receptor immobilization. Biochemistry 36: 9374-9380.
37. Martin, W. L., and P. J. Bjorkman. 1999. Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution. Biochemistry 38: 12639-12647.
38. West, A. P., Jr., and P. J. Bjorkman. 2000. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). Biochemistry 39: 9698-9708.
39. Datta-Mannan, A., D. R. Witcher, Y. Tang, J. Watkins, W. Jiang, and V. J. Wroblewski. 2007. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab. Dispos. 35: 86-94.
40. Firan, M., R. Bawdon, C. Radu, R. J. Ober, D. Eaken, F. Antohe, V. Ghetie, and E. S. Ward. 2001. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int. Immunol. 13: 993-1002.
41. Abdiche, Y. N., Y. A. Yeung, J. Chaparro-Riggers, I. Barman, P. Strop, S. M. Chin, A. Pham, G. Bolton, D. McDonough, K. Lindquist, et al. 2015. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. MAbs 7: 331-343.
42. Sánchez, L. M., D. M. Penny, and P. J. Bjorkman. 1999. Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand. Biochemistry 38: 9471-9476.
43. Gurbaxani, B., L. L. Dela Cruz, K. Chintalacharuvu, and S. L. Morrison. 2006. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol. Immunol. 43: 1462-1473.
44. Schoch, A., H. Kettenberger, O. Mundigl, G. Winter, J. Engert, J. Heinrich, and T. Emrich. 2015. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc. Natl. Acad. Sci. USA 112: 5997-6002.
45. Souders, C. A., S. C. Nelson, Y. Wang, A. R. Crowley, M. S. Klempner, and W. Thomas, Jr. 2015. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. MAbs 7: 912-921.
46. Carter, P., L. Presta, C. M. Gorman, J. B. Ridgway, D. Henner, W. L. Wong, A. M. Rowland, C. Kotts, M. E. Carver, and H. M. Shepard. 1992. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89: 4285-4289.
47. Monnet, C., S. Jorieux, R. Urbain, N. Fournier, K. Bouayadi, C. De Romeuf, C. K. Behrens, A. Fontayne, and P. Mondon. 2015. Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions. Front. Immunol. 6: 39 doi:10.3389/fimmu.2015.00039.
48. Suzuki, T., A. Ishii-Watabe, M. Tada, T. Kobayashi, T. Kanayasu-Toyoda, T. Kawanishi, and T. Yamaguchi. 2010. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J. Immunol. 184: 1968-1976.
49. Warwicker, J., S. Charonis, and R. A. Curtis. 2014. Lysine and arginine content of proteins: computational analysis suggests a new tool for solubility design. Mol. Pharm. 11: 294-303.